TTX-080 for Advanced Metastatic Cancer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Recruiting
Phase 1
Interventional Study
Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 240 (estimated)
- Sponsor
- Tizona Therapeutics, Inc · Industry
Who this trial is looking for
This trial is looking for adults with advanced cancer who have not responded to other treatments. Participants will receive a new therapy called TTX-080, either alone or with other medications.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with advanced metastatic cancer.
- I am 18 years or older.
- I can provide informed consent.
- I have measurable disease.
- I have a performance status of 0 to 1.
- I expect to live at least 12 weeks.
You may not be able to join if
- I have a history of severe allergy to the study treatments.
- I have used an investigational drug in the past 28 days.
- I am receiving high-dose steroids or other immunosuppressive therapy.
- I have a history of severe autoimmune disease.
- I have an uncontrolled illness or another active cancer needing treatment.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies in…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Abbreviated Inclusion Criteria:
1. Subject with histological diagnosis of advanced/metastatic cancer \[currently enrolling in CRC only\]
2. Age 18 years or older, is willing and able to provide informed consent
3. Evidence of measurable disease
4. Eastern Cooperative Oncology Group (ECOG) performan…
Contacts